Cephalon Inc. has appointed J. Kevin Buchi as chief executive officer and a member of the biopharmaceutical company's board.


Cephalon, Kevin Buchi, Frank Baldino Jr., William Egan, chief executive officer, CEO, biopharmaceutical




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Cephalon names Buchi as CEO

December 27th, 2010

FRAZER, Pa. – Cephalon Inc. has appointed J. Kevin Buchi as chief executive officer and a member of the biopharmaceutical company's board.

The move comes following the death of Cephalon founder, chairman and CEO Frank Baldino Jr. earlier this month at age 57 from complications related to leukemia.

Cephalon said it will address the role of chairman in the future and, in the meantime, William Egan will continue to serve as the company's independent presiding director.

With Cephalon for almost 20 years, Buchi assumed day-to-day CEO duties in August. He previously served as chief operating officer and, before that, as chief financial officer.

"Kevin is an experienced pharmaceutical executive who has been involved in every aspect of running our business," stated Egan. "Over the course of many years, Kevin worked closely with Frank Baldino Jr. to create the company that we know today, and he has the passion, leadership skills, organizational abilities and unwavering commitment to patients that are critical to ensuring Cephalon's continued growth and success. He is the clear choice to lead our company."

For the last seven years, Buchi has led the business development function with responsibility for mergers, acquisitions and in-licensing of products, according to Cephalon.

"I am honored to be named chief executive officer and to continue the work of Frank Baldino," Buchi commented. "I had the privilege to work with Frank as we crafted the strategy for leading and growing Cephalon. I intend to continue the same strategic course for the company.

"Cephalon is an extraordinary company with one of the most robust pipelines in the industry focused on patients suffering from rare disorders and diseases for which there are no cures," Buchi added. "We have expanded our global footprint dramatically in the last few years. I am confident that our diverse product portfolio, rich pipeline and global presence position us well for long-term growth and success."

Advertisement